Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients

Blood

Volumn 109, Issue 3, 2007, Pages 1307-1315

  Taylor, Patricia A ^a   Ehrhardt, Michael J ^a   Roforth, Matthew M ^a   Swedin, Jessica M ^a   Panoskaltsis Mortari, Angela ^a   Serody, Jonathan S ^b   Blazar, Bruce R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; ANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW; CELLULAR IMMUNITY; CONTROLLED STUDY; ENGRAFTMENT; GRAFT REJECTION; HUMORAL IMMUNITY; IMAGING; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SERUM; SPLENECTOMY; T CELL DEPLETION; T LYMPHOCYTE;

EID: 33846865333     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-05-022772     Document Type: Article

References (33)

1. Warren RP, Storb R, Weiden PL, Mickelson EM, Thomas ED. Direct and antibody-dependent cell-mediated cytotoxicity against HLA identical sibling lymphocytes: correlation with marrow graft rejections. Transplantation. 1976;22:631-635.
2. Anasetti C, Doney KC, Storb R, et al. Marrow transplantation for severe aplastic anemia: long-term outcome in fifty "untransfused" patients. Ann Intern Med. 1986;104:461-466.
3. Anasetti C, Amos D, Beatty PG, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med. 1989;320:197-204.
4. Barge AJ, Johnson G, Witherspoon R, Torok-Storb B. Antibody-mediated marrow failure after allogeneic bone marrow transplantation. Blood. 1989;74:1477-1480.
5. Warren RP, Storb R, Weiden PL, Su PJ, Thomas ED. Lymphocyte-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity in patients with aplastic anemia: distinguishing transfusion-induced sensitization from possible immune-mediated aplastic anemia. Transplant Proc. 1981;13:245-247.
6. Colson YL, Schuchert MJ, Ildstad ST. The abrogation of allosensitization following the induction of mixed allogeneic chimerism. J Immunol. 2000;165:637-644.
7. Bacigalupo A, Locatelli F, Lanino E, et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAAWorking Party. Bone Marrow Transplant. 2005;36:947-950.
8. Glotz D, Haymann JP, Sansonetti N, et al. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg): a potential tool for transplantation of immunized patients. Transplantation. 1993;56:335-337.
9. Ross CN, Gaskin G, Gregor-Macgregor S, et al. Renal transplantation following immunoadsorption in highly sensitized recipients. Transplantation. 1993;55:785-789.
10. Tyan DB, Li VA, Czer L, Trento A, Jordan SC. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation. 1994;57:553-562.
11. Jordan SC, Quartel AW, Czer LS, et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation. 1998;66:800-805.
12. Vongwiwatana A, Tasanarong A, Hidalgo LG, Halloran PF. The role of B cells and alloantibody in the host response to human organ allografts. Immunol Rev. 2003;196:197-218.
13. Glotz D, Antoine C, Julia P, et al. Intravenous immunoglobulins and transplantation for patients with anti-HLA antibodies. Transpl Int. 2004;17:1-8.
14. Morioka D, Sekido H, Kubota K, et al. Antibody-mediated rejection after adult ABO-incompatible liver transplantation remedied by gamma-globulin bolus infusion combined with plasmapheresis. Transplantation. 2004;78:1225-1228.
15. Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant. 2004;4:1033-1041.
16. Schwartz E, Lapidot T, Gozes D, Singer TS, Reisner Y. Abrogation of bone marrow allograft resistance in mice by increased total body irradiation correlates with eradication of host clonable T cells and alloreactive cytotoxic precursors. J Immunol. 1987;138:460-465.
17. Vallera DA, Blazar BR. T cell depletion for graft-versus-host-disease prophylaxis: a perspective on engraftment in mice and humans. Transplantation. 1989;47:751-760.
18. Cobbold SP, Martin G, Qin S, Waldmann H. Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance. Nature. 1986;323:164-166.
19. Cobbold S, Martin G, Waldmann H. Monoclonal antibodies for the prevention of graft-versus-host disease and marrow graft rejection: the depletion of T cell subsets in vitro and in vivo. Transplantation. 1986;42:239-247.
20. Fleischhauer K, Kernan NA, O'Reilly RJ, Dupont B, Yang SY. Bone marrow-allograft rejection by T lymphocytes recognizing a single amino acid difference in HLA-B44. N Engl J Med. 1990;323:1818-1822.
21. Kernan NA, Flomenberg N, Dupont B, O'Reilly RJ. Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukemia: identification of host-derived antidonor allocytotoxic T lymphocytes. Transplantation. 1987;43:842-847.
22. Pei J, Akatsuka Y, Anasetti C, et al. Generation of HLA-C-specific cytotoxic T cells in association with marrow graft rejection: analysis of alloimmunity by T-cell cloning and testing of T-cell-receptor rearrangements. Biol Blood Marrow Transplant. 2001;7:378-383.
23. Kraus AB, Shaffer J, Toh HC, et al. Early host CD8 T-cell recovery and sensitized anti-donor interleukin-2-producing and cytotoxic T-cell responses associated with marrow graft rejection following nonmyeloablative allogeneic bone marrow transplantation. Exp Hematol. 2003;31:609-621.
24. Sonnenday CJ, Warren DS, Cooper M, et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant. 2004;4:1315-1322.
25. Jordan SC, Vo AA, Nast CC, Tyan D. Use of high-dose human intravenous immunoglobulin therapy in sensitized patients awaiting transplantation: the Cedars-Sinai experience. Clin Transpl. 2003:193-198.
26. Jordan SC. Management of the highly HLA- sensitized patient: a novel role for intravenous gammaglobulin. Am J Transplant. 2002;2:691-692.
27. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with endstage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol. 2004;15:3256-3262.
28. Valujskikh A, Pantenburg B, Heeger PS. Primed allospecific T cells prevent the effects of costimulatory blockade on prolonged cardiac allograft survival in mice. Am J Transplant. 2002;2:501-509.
29. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol. 2001;19:275-290.
30. Takai T. Fc receptors and their role in immune regulation and autoimmunity. J Clin Immunol. 2005;25:1-18.
31. Barnes N, Gavin AL, Tan PS, Mottram P, Koentgen F, Hogarth PM. FcgammaRI-deficient mice show multiple alterations to inflammatory and immune responses. Immunity. 2002;16:379-389.
32. Knezevic-Maramica I, Kruskall MS. Intravenous immune globulins: an update for clinicians. Transfusion. 2003;43:1460-1480.
33. Hancock WW, Gao W, Shemmeri N, et al. Immunopathogenesis of accelerated allograft rejection in sensitized recipients: humoral and nonhumoral mechanisms. Transplantation. 2002;73:1392-1397.